Bharat Biotech’s Typbar TCV gets prequalification from WHO for typhoid fever – Feedback

Bharat Biotech’s Typbar TCV, the Typhoid Conjugate Vaccine against typhoid fever has received prequalification from World Health Organisation (WHO). This enables the procurement and supplies to UNICEF, Pan-American Health Organization (PAHO) and GAVI supported countries.

The company stated that as the world’s first clinically proven Typbar TCV has been evaluated in Human Challenge Studies at Oxford University and typhoid conjugate vaccines have been recommended by WHO’s Strategic Advisory Group of Experts on Immunization (WHO-SAGE).

About news

We take care of publishing the latest investment news and highlights for Feedback

Leave a Reply

Your email address will not be published. Required fields are marked *